Skip to Content

AHIP Comments on Expansion of Induction of Buprenorphine via Telemedicine Encounter

Comment Letter

Comments on the Expansion of Induction of Buprenorphine via Telemedicine Encounter, published in the Federal Register on March 1, 2023.

Document Info

Published on Apr 3, 2023

Download and read the full Resource.

Related Issues

Resource Details


AHIP and our members strongly support the use of medications for opioid use disorder (MOUD) as a valuable tool in helping patients manage opioid use disorder (OUD) and the ability of telemedicine to bring this treatment to patients who might not otherwise be able to access it. The Substance Abuse and Mental Health Services Administration (SAMHSA) has indicated there are no significant differences between telemedicine and in-person buprenorphine for continued substance use treatment, retention in treatment, or engagement in services.